-
Breakout Capital
Ultimate Breakouts with Alan Green 4 October 2025 The deep dive with Alan Green, “Ultimate Breakouts”
-
Exercise of Warrants; Total Voting Rights
ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that the Company has received notice of exercise of 500,000 warrants over New Ordinary Shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £25,000. New Ordinary Shares and Admission The New Ordinary Shares have been…
-
Stock House
“Putting Patients into Remission”: ImmuPharma’s Autoimmune Breakthrough with P140 16 September 2025 CEO, Tim McCarthy joins Stockhouse – “Putting Patients into Remission”: ImmuPharma’s Autoimmune Breakthrough with P140
-
Zaks Traders Cafe
Zak Mir talks to Tim McCarthy, CEO Immupharma 12 September 2025 Zak Mir talks to Tim McCarthy, CEO Immupharma, in the wake of the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announcing the filing of a groundbreaking new patent application for its lead asset P140, the world’s first “Immunormalizer.”
-
Exercise of Warrants; Total Voting Rights
ImmuPharma plc (LSE : IMM), the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announces that the Company has received notice of exercise of 2,500,000 warrants over New Ordinary Shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £125,000. The New Ordinary Shares have been allotted today and…
-
Sunday Roast
Midweek Takeaway – Tim McCarthy, CEO,& Dr Sébastien Goudreau, newly appointed CSO of ImmuPharma 5 September 2025 Tim McCarthy, CEO, and Dr Sébastien Goudreau, CSO, joins Sunday Roast Podcast to discuss a groundbreaking patent for its lead asset P140, the world’s first “Immunormalizer,” – September 2025
-
Proactive
ImmuPharma CEO & CSO on major patent milestone for P140 autoimmune therapy 2 September 2025 ImmuPharma’s CEO Tim McCarthy and CSO Dr Sébastien Goudreau talk with Proactive Investor about the Company’s latest milestone — the filing of a new patent application for its lead autoimmune drug therapy, P140, described as the world’s first “immunormaliser’ –…
-
Appointments of Chief Scientific Officer and Head of R&D
ImmuPharma PLC (LSE: IMM), a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announces key appointments, in conjunction with the filing of a groundbreaking new patent application for its lead asset P140, separately announced today. Recognising the significance of this major step forward, Dr Sébastien Goudreau has been promoted into the position of Chief…
-
ImmuPharma Files Groundbreaking New Patent Application for P140: First-in-Class ‘Immunormalizer’ for Precision Diagnosis and Treatment of Autoimmune Diseases
ImmuPharma PLC (LSE: IMM), a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, today announces the filing of a groundbreaking new patent application for its lead asset P140, the world’s first “Immunormalizer.” The patent application which provides the potential for 20 years of commercial exclusivity, discloses a novel diagnostic test and precision treatment approach,…
-
TR1 from Lanstead Capital – Major interest in shares
Standard form for notification of major holdings To view click here
